Cargando…
Mifepristone Repurposing in Treatment of High-Grade Gliomas
Glioma is the most common and aggressive primary tumor of the central nervous system. The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy. Unfortunately, this treatment has not produced an adequate patient response, resulting in a median survival time of 12–15 month...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930566/ https://www.ncbi.nlm.nih.gov/pubmed/33680961 http://dx.doi.org/10.3389/fonc.2021.606907 |
_version_ | 1783660122769195008 |
---|---|
author | Llaguno-Munive, Monserrat Vazquez-Lopez, Maria Ines Jurado, Rafael Garcia-Lopez, Patricia |
author_facet | Llaguno-Munive, Monserrat Vazquez-Lopez, Maria Ines Jurado, Rafael Garcia-Lopez, Patricia |
author_sort | Llaguno-Munive, Monserrat |
collection | PubMed |
description | Glioma is the most common and aggressive primary tumor of the central nervous system. The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy. Unfortunately, this treatment has not produced an adequate patient response, resulting in a median survival time of 12–15 months and a 5-year overall survival of <5%. Although new strategies have been sought to enhance patient response, no significant increase in the global survival of glioma patients has been achieved. The option of developing new drugs implies a long and costly process, making drug repurposing a more practical alternative for improving glioma treatment. In the last few years, researchers seeking more effective cancer therapy have pursued the possibility of using anti-hormonal agents, such as mifepristone. The latter drug, an antagonist for progesterone and glucocorticoid receptors, has several attractive features: anti-tumor activity, low cytotoxicity to healthy cells, and modulation of the chemosensitivity of several cancer cell lines in vitro. Hence, the addition of mifepristone to temozolomide-based glioblastoma chemotherapy may lead to a better patient response. The mechanisms by which mifepristone enhances glioma treatment are not yet known. The current review aims to discuss the potential role of mifepristone as an adjuvant drug for the treatment of high-grade gliomas. |
format | Online Article Text |
id | pubmed-7930566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79305662021-03-05 Mifepristone Repurposing in Treatment of High-Grade Gliomas Llaguno-Munive, Monserrat Vazquez-Lopez, Maria Ines Jurado, Rafael Garcia-Lopez, Patricia Front Oncol Oncology Glioma is the most common and aggressive primary tumor of the central nervous system. The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy. Unfortunately, this treatment has not produced an adequate patient response, resulting in a median survival time of 12–15 months and a 5-year overall survival of <5%. Although new strategies have been sought to enhance patient response, no significant increase in the global survival of glioma patients has been achieved. The option of developing new drugs implies a long and costly process, making drug repurposing a more practical alternative for improving glioma treatment. In the last few years, researchers seeking more effective cancer therapy have pursued the possibility of using anti-hormonal agents, such as mifepristone. The latter drug, an antagonist for progesterone and glucocorticoid receptors, has several attractive features: anti-tumor activity, low cytotoxicity to healthy cells, and modulation of the chemosensitivity of several cancer cell lines in vitro. Hence, the addition of mifepristone to temozolomide-based glioblastoma chemotherapy may lead to a better patient response. The mechanisms by which mifepristone enhances glioma treatment are not yet known. The current review aims to discuss the potential role of mifepristone as an adjuvant drug for the treatment of high-grade gliomas. Frontiers Media S.A. 2021-02-18 /pmc/articles/PMC7930566/ /pubmed/33680961 http://dx.doi.org/10.3389/fonc.2021.606907 Text en Copyright © 2021 Llaguno-Munive, Vazquez-Lopez, Jurado and Garcia-Lopez http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Llaguno-Munive, Monserrat Vazquez-Lopez, Maria Ines Jurado, Rafael Garcia-Lopez, Patricia Mifepristone Repurposing in Treatment of High-Grade Gliomas |
title | Mifepristone Repurposing in Treatment of High-Grade Gliomas |
title_full | Mifepristone Repurposing in Treatment of High-Grade Gliomas |
title_fullStr | Mifepristone Repurposing in Treatment of High-Grade Gliomas |
title_full_unstemmed | Mifepristone Repurposing in Treatment of High-Grade Gliomas |
title_short | Mifepristone Repurposing in Treatment of High-Grade Gliomas |
title_sort | mifepristone repurposing in treatment of high-grade gliomas |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930566/ https://www.ncbi.nlm.nih.gov/pubmed/33680961 http://dx.doi.org/10.3389/fonc.2021.606907 |
work_keys_str_mv | AT llagunomunivemonserrat mifepristonerepurposingintreatmentofhighgradegliomas AT vazquezlopezmariaines mifepristonerepurposingintreatmentofhighgradegliomas AT juradorafael mifepristonerepurposingintreatmentofhighgradegliomas AT garcialopezpatricia mifepristonerepurposingintreatmentofhighgradegliomas |